KIYATEC

company

About

KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies.

Details

Last Funding Type
Series C
Last Funding Money Raised
$18M
Industries
Biotechnology,Health Diagnostics,Life Science
Founded date
Jan 1, 2005
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
KIYATEC Inc.

KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co‐culture, and is a single-use disposable. 3DKUBE cell‐based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
11
$30.94M
KIYATEC has raised a total of $30.94M in funding over 2 rounds. Their latest funding was raised on Dec 12, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 12, 2022 Series C $18M 4 Bruker Detail
Apr 30, 2021 Series Unknown $2.50M 2 Seae Ventures Detail
May 1, 2019 Series B $3M 2 VentureSouth Detail
Dec 15, 2017 Convertable Note $2.20M 1 Detail
Dec 15, 2015 Series B $2.85M 1 Detail

Investors

Number of Lead Investors
Number of Investors
4
6
KIYATEC is funded by 6 investors. Bruker and NMT Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Bruker Yes Series C
NMT Capital Yes Series A
LabCorp Series C
Seae Ventures Series C
VentureSouth Series C
Upstate Carolina Angel Network Series A

Employee Profiles

Number of Employee Profiles
5
KIYATEC has 5 current employee profiles, including Board member Jason Robart
Board member
Executive
Executive
Executive
Executive